Highly effective antibodies identified, may lead to passive COVID-19 vaccine

▴ Highly effective antibodies identified, may lead to passive COVID-19 vaccine
Unlike in active vaccination, passive vaccination involves the administration of ready-made antibodies, which are degraded after some time.

Scientists have identified highly effective antibodies against the novel coronavirus, which they say can lead to the development of a passive vaccination for COVID-19.

Unlike inactive vaccination, passive vaccination involves the administration of ready-made antibodies, which are degraded after some time.

However, the effect of a passive vaccination is almost immediate, whereas with an active vaccination it has to build up first, the researchers said.

The research, published in the journal Cell, also shows that some SARS-CoV-2 antibodies bind to tissue samples from various organs, which could potentially trigger undesired side effects.

The scientists at the German Center for Neurodegenerative Diseases (DZNE) and Charite - Universitatsmedizin Berlin isolated almost 600 different antibodies from the blood of individuals who had overcome COVID-19, the disease triggered by SARS-CoV-2.

Using laboratory tests, they were able to narrow this number down to a few antibodies that were particularly effective at binding to the virus.

The researchers then produced these antibodies artificially using cell cultures.

The so-called neutralizing antibodies bind to the virus, as crystallographic analysis reveals, and thus prevent the pathogen from entering cells and reproducing, they said.

Also, virus recognition by antibodies helps immune cells to eliminate the pathogen. Studies in hamsters -- which, like humans, are susceptible to infection by SARS-CoV-2 -- confirmed the high efficacy of the selected antibodies.

"If the antibodies were given after infection, the hamsters developed mild disease symptoms at most. If the antibodies were applied preventively -- before infection -- the animals did not get sick," said Jakob Kreye, coordinator of the research project.

The researchers noted that treating infectious diseases with antibodies has a long history.

For COVID-19, this approach is also being investigated through the administration of plasma-derived from the blood of recovered patients. With the plasma, antibodies of donors are transferred, they said.

"Ideally, the most effective antibody is produced in a controlled manner on an industrial scale and in constant quality. This is the goal we are pursuing," said Momsen Reincke, first author of the research.

"Three of our antibodies are particularly promising for clinical development," explained Harald Pruss, a research group leader at the DZNE and also a senior physician at Charite - Universitatsmedizin Berlin.

"Using these antibodies, we have started to develop a passive vaccination against SARS-CoV-2," Pruss said.

In addition to the treatment of patients, preventive protection of healthy individuals who have had contact with infected persons is also a potential application, the researchers said.

How long the protection lasts will have to be investigated in clinical studies, they said.

"This is because, unlike in active vaccination, passive vaccination involves the administration of ready-made antibodies, which are degraded after some time," Pruss said. In general, the protection provided by a passive vaccination is less persistent than that provided by an active vaccination, the researchers said.

However, the effect of a passive vaccination is almost immediate, whereas with an active vaccination it has to build up first, they said.

"It would be best if both options were available so that a flexible response could be made depending on the situation," Pruss added.

Tags : #COVID-19 #Passive #Vaccine #Antibodies

About the Author


Dr. Naila Syed

A well presented, self-motivated, and confident writer. Passionate about educating the masses on medical and nonmedical ways to promote health and lifestyle through my mighty pen.You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

To stay well during festive seasonOctober 21, 2020
The fastest growing and the most awarded Cath Lab of India in 2018 is bringing affordable and accessible healthcare available for cardiovascular diseases in India saOctober 21, 2020
ViiV healthcare development program on cabotegravir and rilivirine has no pandemic interruptionsOctober 21, 2020
No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study October 21, 2020
India sustains the continued trend of consistent decline in Active CasesOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Haryana tops Anemia Mukt Bharat Index in countryOctober 21, 2020
Covid Update: Assam & OdishaOctober 21, 2020
BriaCell announces the overall breast cancer survival (OS) data of its lead product candidate, Bria-IMT™October 21, 2020
Teladoc Health Data Shows Broadening Mental Health Care DemandOctober 21, 2020
China vaccinated 60,000 people: Result awaited October 21, 2020
Lilly hires outside advisor for COVID drug plant problemsOctober 21, 2020
No Child Mothers, Accelerating the reduction of adolescent pregnancies on occasion of Adolescent Pregnancy Prevention Week October 21, 2020
Tyber Medical receives US FDA clearance on foot and ankle plating systemsOctober 21, 2020
Green tea and coffee connected to lower death risk in people with diabetesOctober 21, 2020
MEDICAL FESTIVAL ASIA: Events for the region’s medical and healthcare sectorOctober 21, 2020
Selecta Biosciences and Asklepios BioPharmaceutical receives US FDA approval for their gene therapyOctober 21, 2020
Astellas Pharma received US FDA approval for the treatment of primary mitochondrial myopathiesOctober 21, 2020
GSK presents positive clinical data on maternal and older adults RSV candidate vaccinesOctober 21, 2020